THE ALMAC GROUP SHOWCASE RECENT EXPANSIONS AT INFORMEX 2016
Almac Group will be showcasing their recent expansion news expanding on their Biocatalysis and Pharmaceutical Development Services.
On 03 November 2015 Almac Group, the global contract development and manufacturing organisation, announced the acquisition of 100% shares of Arran Chemical Company, an independent and privately owned organisation based in Athlone, Ireland. The addition of Arran Chemical Company marks a new chapter in Almac’s continuous growth, with significant increase in scale (a range of reactors up to 6,300L and total capacity of up to 45m3) the new combined business will integrate Biocatalysis technology with large scale intermediates manufacture. Almac will be exhibiting alongside Arran at this year’s InformEx showcasing their range of services within Biocatalysis.
Following on from the acquisition of Arran, on 09 November 2015, it was then confirmed that Almac would invest £16 million to expand its Formulation and Analytical Development services to meet ongoing client demand. The company announced the successful conclusion to negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England – a world-class science, technology and enterprise park. Specifically, Almac will occupy the Formulation Development and Analytical testing facilities at the site which will complement existing development & GMP services offered from its Craigavon NI Headquarters.
Why not stop by Almac’s booth, number 1211, to learn more about their recent expansions. Almac also invite you to join them on 2nd February, 2016 at 11.40 AM in room 218 where Prof. Tom Moody, Head of Biocatalysis, will present on "Biocatalysis - Gene to GMP".
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
For more information visit www.almacgroup.com or e-mail firstname.lastname@example.org.